- BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform
- BioVaxys filed an international patent application through the Patent Cooperation Treaty (“PCT”) for BVX-1021, its vaccine for SARS1 and other sarbecoviruses
- CEO James Passin sat down with Sabrina Cuthbert to discuss the news
- BioVaxys Technology is a clinical-stage biotechnology company that is developing viral and oncology vaccine platforms
- BioVaxys Technology Corp. (BIOV) opened trading at C$0.11 per share.
BioVaxys Technology Corp. (BIOV) has broadened patent coverage for its viral vaccine platform.
BioVaxys filed an international patent application through the Patent Cooperation Treaty (“PCT”) for BVX-1021, it’s vaccine for SARS1 and other sarbecoviruses.
BVX-1021 is the subject of an ongoing research collaboration between The Ohio State University and BioVaxys that is evaluating the Company’s novel approach for a ‘universal vaccine’ that can treat a broad range of sarbecoviruses.
An International PCT Application, which is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single ‘international’ patent application.
CEO James Passin sat down with Sabrina Cuthbert to discuss the news.
BioVaxys Technology is a clinical-stage biopharma company. The company develops antiviral and anticancer vaccine platforms to treat SARS-CoV-2 and other viral infections, as well as ovarian cancer and other solid tumour types.
BioVaxys Technology Corp. (BIOV) opened trading at C$0.11 per share.
